Page 31 - GPD-2-4

Gene & Protein in Disease The roles and mechanisms of ETS1 in diseases

63. Bukavina L, Bensalah K, Bray F, et al., 2022, Epidemiology of 71. Gabler L, Lotsch D, Kirchhofer D, et al., 2019, TERT
renal cell carcinoma: 2022 update. Eur Urol, 82(5): 529–542. expression is susceptible to BRAF and ETS-factor inhibition
in BRAF(V600E)/TERT promoter double-mutated glioma.
https://doi.org/10.1016/j.eururo.2022.08.019
Acta Neuropathol Commun, 7(1): 128.
64. Yang X, Zhang Y, Fan H, 2021, Downregulation of SBF2-AS1 https://doi.org/10.1186/s40478-019-0775-6
functions as a tumor suppressor in clear cell renal cell
carcinoma by inhibiting miR-338-3p-targeted ETS1. Cancer 72. Dittmer J, 2003, The biology of the Ets1 proto-oncogene.
Gene Ther, 28(7–8): 813–827. Mol Cancer, 2: 29.
https://doi.org/10.1038/s41417-020-0197-4 https://doi.org/10.1186/1476-4598-2-29
65. Pan G, Zhang J, You F, et al., 2022, ETS proto-oncogene 73. Priebe V, Sartori G, Napoli S, et al., 2020, Role of ETS1 in the
1-activated muskelin 1 antisense RNA drives the malignant transcriptional network of diffuse large B cell lymphoma of
progression of hepatocellular carcinoma by targeting miR- the activated B cell-like type. Cancers (Basel), 12(7): 1912.
22-3p to upregulate ETS Proto-Oncogene 1. Bioengineered, https://doi.org/10.3390/cancers12071912
13(1): 1346–1358.
74. Overbeck BM, Martin-Subero JI, Ammerpohl O, et al., 2012,
https://doi.org/10.1080/21655979.2021.2017565 ETS1 encoding a transcription factor involved in B-cell
differentiation is recurrently deleted and down-regulated
66. Sun Y, Zhang H, Ma R, et al., 2023, ETS-1-activated
LINC01016 over-expression promotes tumor progression in classical Hodgkin’s lymphoma. Haematologica, 97(10):
via suppression of RFFL-mediated DHX9 ubiquitination 1612–1614.
degradation in breast cancers. Cell Death Dis, 14(8): 507. https://doi.org/10.3324/haematol.2012.061770
https://doi.org/10.1038/s41419-023-06016-3 75. Bonetti P, Testoni M, Scandurra M, et al., 2013, Deregulation
of ETS1 and FLI1 contributes to the pathogenesis of diffuse
67. Vallarelli AF, Rachakonda PS, Andre J, et al., 2016, TERT large B-cell lymphoma. Blood, 122(13): 2233–2241.
promoter mutations in melanoma render TERT expression
dependent on MAPK pathway activation. Oncotarget, 7(33): https://doi.org/10.1182/blood-2013-01-475772
53127–53136. 76. Chung EYL, Sartori G, Ponzoni M, et al., 2023, ETS1
https://doi.org/10.18632/oncotarget.10634 phosphorylation at threonine 38 is associated with the cell
of origin of diffuse large B cell lymphoma and sustains the
68. Li Y, Zhou QL, Sun W, et al., 2015, Non-canonical NF-kappaB growth of tumour cells. Br J Haematol, 203(2): 244–254.
signalling and ETS1/2 cooperatively drive C250T mutant
TERT promoter activation. Nat Cell Biol, 17(10): 1327–1338. https://doi.org/10.1111/bjh.19018
https://doi.org/10.1038/ncb3240 77. McCarter AC, Della Gatta G, Melnick A, et al., 2020,
Combinatorial ETS1-dependent control of oncogenic
69. Kohli JS, Mir H, Wasif A, et al., 2017, ETS1, nucleolar and NOTCH1 enhancers in T-cell leukemia. Blood Cancer
non-nucleolar TERT expression in nevus to melanoma Discov, 1(2): 178–197.
progression. Oncotarget, 8(61): 104408–104417.
https://doi.org/10.1158/2643-3230.BCD-20-0026
https://doi.org/10.18632/oncotarget.22254
78. Luchtel RA, Zhao Y, Aggarwal RK, et al., 2022, ETS1 is a
70. Xu X, Li Y, Bharath SR, et al., 2018, Structural basis for novel transcriptional regulator of adult T-cell leukemia/
reactivating the mutant TERT promoter by cooperative lymphoma of North American descent. Blood Adv, 6(20):
binding of p52 and ETS1. Nat Commun, 9(1): 3183. 5613–5624.
https://doi.org/10.1038/s41467-018-05644-0 https://doi.org/10.1182/bloodadvances.2022007725

Volume 2 Issue 4 (2023) 10 https://doi.org/10.36922/gpd.2141